文献速递胸部肿瘤支持与姑息治疗

非小细胞肺癌在弱势与特殊人群中的个性化诊疗

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.
PubMed 文献 · J Thorac Oncol · 2026-03-31

该综述聚焦非小细胞肺癌(NSCLC)中在关键研究中代表性不足的特殊人群,包括青少年与年轻成人、女性、妊娠患者、携带可靶向基因组变异或胚系致病突变者、免疫抑制患者(含慢性病毒感染)、老年人、脑转移患者及第二原发肺癌幸存者。文章综合现有证据,讨论这些人群在疾病生物学、基因组特征、药理学差异及心理社会伦理方面的独特考量,并指出诊断可及性、试验资格和支持治疗方面的持续差异。综述还探讨了脑穿透性靶向治疗、免疫联合治疗和抗体药物偶联物等现代系统治疗在代表性不足人群中的安全性、有效性及长期后果需专门评估,最后提出加强精准肿瘤学包容性的研究方向。

要点

  • 特殊NSCLC人群在关键研究中代表性不足,限制证据外推和公平精准诊疗。
  • 不同人群的疾病生物学、基因组格局及药理学随年龄和性别存在差异。
  • 诊断可及性、试验资格和支持治疗方面的差异仍是主要障碍。

核心结论

  • 解决代表性、试验方法和结构性不平等方面的长期差距,对确保近期治疗进展惠及全部NSCLC患者至关重要。

研究设计与样本

  • 本文为综述,综合弱势与特殊NSCLC人群的当代证据,讨论临床实践、支持治疗、生存者管理及研究设计的启示。

主要发现

  • 青少年与年轻成人、女性、妊娠患者、携带可靶向基因组变异或胚系致病突变者、免疫抑制患者(含慢性病毒感染)、老年人、脑转移患者及第二原发肺癌幸存者在研究中持续代表性不足。
  • 分子检测和靶向治疗改善了部分亚组结局,但诊断可及性、试验资格和支持治疗方面的差异仍是主要障碍。
  • 脑穿透性靶向治疗、免疫联合治疗和抗体药物偶联物拓宽了治疗选择,但其在代表性不足人群中的安全性、有效性和长期后果需专门评估。

临床怎么用

  • 临床决策需考虑特殊人群的疾病生物学、基因组格局、年龄与性别相关药理学差异及心理社会伦理因素。
  • 应关注诊断可及性、试验资格和支持治疗方面的差异,以推动公平的精准肿瘤学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NSCLC encompasses a heterogeneous patient population whose clinical needs, biological features, and treatment outcomes differ substantially from those represented in pivotal studies. Adolescents and young adults, women, pregnant patients, individuals with actionable genomic alterations or constitutional pathogenic variants, immunocompromised patients, including those with chronic viral infections, older adults, patients with brain metastases, and survivors with second primary lung cancers remain consistently underrepresented in research programs. This limits the generalizability of current evidence and challenges the delivery of equitable precision oncology. Across these populations, distinct disease biology, differential genomic landscapes, sex- and age-related variations in pharmacology, and complex psychosocial or ethical considerations shape clinical decision-making. Advances in molecular testing and targeted therapies have improved outcomes for some subgroups; however, persistent disparities in diagnostic access, trial eligibility, and supportive care remain major barriers. In parallel, modern systemic agents including brain-penetrant targeted therapies, immunotherapy combinations, and antibody-drug conjugates have broadened therapeutic options, although their safety, effectiveness, and long-term consequences require dedicated evaluation in underrepresented populations. This review synthesizes contemporary evidence from these special NSCLC populations, highlighting shared challenges and unique considerations. We discuss implications for clinical practice, supportive care, survivorship, and research design and outline opportunities to strengthen inclusivity in precision oncology. Addressing longstanding gaps in representation, trial methodology, and structural inequities is essential to ensure that recent therapeutic advances translate into improved outcomes for the full spectrum of patients living with NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Parisi C, De Giglio A, Banini M, et al. NSCLC in Vulnerable and Special Populations: Toward Personalized Care. J Thorac Oncol. 2026. PMID: 41921747. doi:10.1016/j.jtho.2026.103705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。